Home › Compare › ROSYY vs ABBV
ROSYY yields 198.02% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 10
Combined, ROSYY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ROSYY + ABBV for your $10,000?
Public Joint Stock Company Rostelecom provides digital services and solutions in Russia. The company provides Rostelecom Key, an ecosystem of services for households that offers smart intercom, smart gate bar, and smart meter solutions, as well as integrated video surveillance platform; Pay TV; Wink, a digital video services; and smart home services. It also offers antivirus solutions; Wi-Fi 2.0 platform; corporate TV's; virtual BX; toll-free calling 8-800; Game-RT-X routers; IT solutions for municipal solid waste management; video surveillance services; and VDI/VDC and cyber security services. In addition, the company offers NVIDIA, a cloud gaming service; Kapsula, a smart speaker; submarine cables; R&D; maintenance and recreational; engineering design; data and data storage; telecommunication and IT consulting; and engages in leasing of equipment, communication equipment manufacturing, retail, real estate, and venture and pension fund activities. Further, it provides solutions for electronic government, cybersecurity, data center and cloud-based services, biometrics, healthcare, education, house maintenance, and utility services. The company was incorporated in 1993 and is headquartered in Moscow, Russia.
Full ROSYY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.